Tendinitis Treatment Industry Companies

Latest Americas and Europe Tendinitis Treatment Companies Update

• 
  Nov 2023: The data on Merck's chronic cough medication do not offer enough proof to demonstrate its clinical value for patients, according to advisors to the US health regulator, who made this statement on Friday. The late-stage data for the medication gefapixant, which showed a slight decrease in cough frequency when compared to a placebo, was rejected by the FDA panel of the United States by a vote of 12 to 1. Adverse effects, including taste loss, were also reported by patients receiving the medication. The FDA advisers questioned the drug's efficacy, citing a significant patient dropout rate, even though they said its adverse effects were tolerable. Merck's late-stage data revealed that 22% of patients received excessive dosages of the medication and discontinued the treatment due to adverse events.

• 
  May 2023: Ingelheim, Germany-based Boehringer Ingelheim has started construction on a new Chemical Innovation Plant at company headquarters. The key to the significant €285 million investment was laid in the presence of Rhineland-Palatinate Minister-President and German Chancellor. This facility will create pharmaceuticals for clinical trial phases and manufacturing methods for APIs or active pharmaceutical ingredients starting in 2026. According to the corporation, completing this phase is essential to moving novel medication ideas quickly from the research pipeline to clinical studies and, eventually, market approval.

• Abbott (U.S.)


• Pfizer (U.S.)


• AstraZeneca (U.K)


• Bayer (Germany)


• Merck & Co. Inc. (Germany)


• GlaxoSmithKline plc (U.S.)


• Teva Pharmaceutical Industries (Israel)


• Boehringer Ingelheim Pharmaceuticals, Inc. (Germany)